Talaris Therapeutics TALS Stock
Talaris Therapeutics Price Chart
Talaris Therapeutics TALS Financial and Trading Overview
| Talaris Therapeutics stock price | 2.72 USD |
| Previous Close | 2.48 USD |
| Open | 2.48 USD |
| Bid | 0 USD x 800 |
| Ask | 0 USD x 800 |
| Day's Range | 2.43 - 2.5 USD |
| 52 Week Range | 0.89 - 8.5 USD |
| Volume | 106.44K USD |
| Avg. Volume | 289.99K USD |
| Market Cap | 107.42M USD |
| Beta (5Y Monthly) | 2.268661 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | 0 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.5 USD |
TALS Valuation Measures
| Enterprise Value | -59969256 USD |
| Trailing P/E | N/A |
| Forward P/E | -8.266666 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 0.6426535 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | 0.788 |
Trading Information
Talaris Therapeutics Stock Price History
| Beta (5Y Monthly) | 2.268661 |
| 52-Week Change | -68.92% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 8.5 USD |
| 52 Week Low | 0.89 USD |
| 50-Day Moving Average | 2.53 USD |
| 200-Day Moving Average | 2.04 USD |
TALS Share Statistics
| Avg. Volume (3 month) | 289.99K USD |
| Avg. Daily Volume (10-Days) | 269.81K USD |
| Shares Outstanding | 42.17M |
| Float | 18.2M |
| Short Ratio | 2.64 |
| % Held by Insiders | 13.48% |
| % Held by Institutions | 76.34% |
| Shares Short | 917.07K |
| Short % of Float | 3.52% |
| Short % of Shares Outstanding | 2.16% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -23.68% |
| Return on Equity (ttm) | -40.29% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -76138000 USD |
| Net Income Avi to Common (ttm) | -78132000 USD |
| Diluted EPS (ttm) | -1.84 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 165.81M USD |
| Total Cash Per Share (mrq) | 3.93 USD |
| Total Debt (mrq) | 1.27M USD |
| Total Debt/Equity (mrq) | 0.79 USD |
| Current Ratio (mrq) | 16.589 |
| Book Value Per Share (mrq) | 3.859 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -61479000 USD |
| Levered Free Cash Flow (ttm) | -33683500 USD |
Profile of Talaris Therapeutics
| Country | United States |
| State | MA |
| City | Wellesley |
| Address | 93 Worcester Street |
| ZIP | 02481 |
| Phone | 502-398-9250 |
| Website | https://talaristx.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 84 |
Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR001 for the patients with a severe form of scleroderma. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Wellesley, Massachusetts.
Q&A For Talaris Therapeutics Stock
What is a current TALS stock price?
Talaris Therapeutics TALS stock price today per share is 2.72 USD.
How to purchase Talaris Therapeutics stock?
You can buy TALS shares on the NasdaqGM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Talaris Therapeutics?
The stock symbol or ticker of Talaris Therapeutics is TALS.
Which industry does the Talaris Therapeutics company belong to?
The Talaris Therapeutics industry is Biotechnology.
How many shares does Talaris Therapeutics have in circulation?
The max supply of Talaris Therapeutics shares is 43.96M.
What is Talaris Therapeutics Price to Earnings Ratio (PE Ratio)?
Talaris Therapeutics PE Ratio is 0.00000000 now.
What was Talaris Therapeutics earnings per share over the trailing 12 months (TTM)?
Talaris Therapeutics EPS is 0 USD over the trailing 12 months.
Which sector does the Talaris Therapeutics company belong to?
The Talaris Therapeutics sector is Healthcare.
Talaris Therapeutics TALS included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
| NASDAQ Global Market Composite NQGM | 2160.36 USD — |
-2.45
|
— — | 2147.48 USD — | 2200.33 USD — | — - | — — |
| NASDAQ Biotechnology NBI | 4195.13 USD — |
-2.14
|
— — | 4174.1 USD — | 4266.29 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
| Stlmt ID NASDAQ Biotechnology NBX | 4604.4 USD — |
-2.98
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
- {{ link.label }} {{link}}